Australia TGA GMP (PIC/S Guide PE009, as adopted via the Manufacturing Principles Determination) Audit-Readiness Rubric — Regscribe v0

(Therapeutic Goods Administration — Therapeutic Goods Act 1989, s.36 Manufacturing Principles)

Scope boundary — read this before scoring anything. Australia does not write its own independent GMP code. The Therapeutic Goods Administration (TGA), a founding member of the Pharmaceutical Inspection Co-operation Scheme (PIC/S), gives the PIC/S Guide to Good Manufacturing Practice (PE009) direct legal force in Australia by naming it, edition-by-edition, inside a legislative instrument:

• Therapeutic Goods Act 1989, section 36 — empowers the Minister for Health to determine "manufacturing principles" that therapeutic-goods manufacturers must observe.
• Therapeutic Goods (Manufacturing Principles) Determination 2020 — the legislative instrument made under s.36. Its operative text states that manufacture of medicines, active pharmaceutical ingredients (APIs), and sunscreens must comply with the PIC/S Guide to GMP, naming a specific PE009 edition, and is periodically re-made/updated to point at newer PE009 editions as PIC/S revises the Guide. This is the direct legal-force mechanism — the PIC/S Guide itself is a PIC/S-scheme publication, not Australian law, but this Determination's incorporation of it makes its clauses enforceable in Australia.
• Therapeutic Goods Act 1989, section 40 — requires the holder of a manufacturing licence to "observe the manufacturing principles" as a licence condition; breach is a licence-condition breach with escalating civil/criminal consequences depending on harm caused.
• Therapeutic Goods Regulations 1990, Schedule 7 (goods exempt from the manufacturing principles) and Schedule 8 (persons exempt) — gate which products/manufacturers this entire rubric even applies to.

What is genuinely TGA-specific vs. what is pure PIC/S text (do not conflate these when scoring):

1. TGA excludes three PIC/S annexes outright. Per the current Determination, Australia adopts the PIC/S Guide to GMP – 25 August 2023 (PE009-17) in full except Annexes 4, 5, and 14:
   • Annexes 4 and 5 (Manufacture of Veterinary Medicinal Products / Immunological Veterinary Medicinal Products) — excluded because veterinary/agricultural chemical products in Australia are regulated by the Australian Pesticides and Veterinary Medicines Authority (APVMA), not the TGA. A document review that cites Annex 4/5 against a TGA-regulated human drug manufacturer is citing the wrong regulator's annex.
   • Annex 14 (Manufacture of Products derived from Human Blood or Plasma) — excluded because Australia maintains its own Australian Code of Good Manufacturing Practice for human blood and blood components, human tissues, and human cellular therapy products (Version 1.0, April 2013) as the applicable standard for that product category instead of the PIC/S annex. This rubric does not cover that separate Code — flagged as a candidate future rubric, not folded in here.
2. TGA layers a compliance-flexibility clause on top of PIC/S text: a manufacturer may deviate from a PIC/S GMP procedure if it demonstrates, to the TGA's satisfaction, that not adopting that specific procedure does not increase risk. This "alternative approach" provision is a TGA/Determination-level concept, not PIC/S wording itself, and should be treated as a genuine (if narrow) escape valve when scoring an apparent non-conformance — check for a documented, TGA-accepted risk rationale before treating a PE009 deviation as an automatic finding.
3. TGA runs its own licensing/clearance administrative layer around the PIC/S text, which has no PIC/S-text analogue at all:
   • Domestic manufacturers (site in Australia) need an Australian manufacturing licence issued by the TGA.
   • Overseas manufacturers supplying into Australia need TGA GMP clearance, via one of three pathways: Mutual Recognition Agreement (MRA) evidence (for manufacturers in an MRA-partner jurisdiction — historically EU/EEA states, Singapore, and others with a GMP-mutual-recognition arrangement with Australia), Compliance Verification (CV) (desktop assessment of another PIC/S-member regulator's inspection evidence, for non-MRA PIC/S countries), or TGA GMP Certification (a TGA-conducted onsite inspection, used when neither MRA nor CV evidence is available). This three-pathway structure, and the licence-vs-clearance domestic/overseas split itself, is pure TGA administrative law — it has no equivalent inside the PIC/S Guide's own text, which only describes manufacturing quality requirements, not who has to prove them to which regulator by which route.
   • Manufacturing licences and GMP clearances/certificates can be suspended, revoked, or cancelled by the TGA (voluntarily by the holder, or imposed), which can in turn trigger cancellation of the affected product(s) from the Australian Register of Therapeutic Goods (ARTG) — after which the product cannot lawfully be imported, manufactured, exported, or supplied in Australia.
4. Version/edition churn is a live, TGA-specific scoring hazard. Because the Determination points at a specific dated PE009 edition rather than "whatever PIC/S currently publishes," Australia can lag or phase in a new PIC/S edition on its own timetable — e.g. PE009-16 (1 Feb 2022) was adopted into the Australian Determination effective 3 June 2024 (with Annex 16 given a further phase-in to 3 September 2024), and PE009-17 (25 Aug 2023) — whose only material change from PE009-16 is a rewritten Annex 1 (sterile manufacturing) — takes effect in Australia from 1 September 2025. A document-analysis tool must confirm which PE009 edition was legally in force in Australia on the date the document under review was created/effective, not simply cite the newest global PE009 edition — Regscribe's rubric-matching logic should carry an edition-effective-date table, not a single static "current PE009" pointer.

Sources used

Regulatory text / legal structure (primary):

• Therapeutic Goods Act 1989, s.36 and s.40 — existence, section numbers, and general effect (Minister's power to determine manufacturing principles; licence-holder obligation to observe them) confirmed via WebSearch across TGA's own pages and independent legal/regulatory-affairs summaries (seerpharma.com, Freyr, SGS Systems Global). The Act's own full text was not independently fetched and read this session — direct WebFetch attempts against tga.gov.au pages timed out repeatedly (see Fetch-failure note below), so section-level claims here rest on consistent secondary-source corroboration, not a primary-text read, and should be treated with the same caution as a WebSearch-only citation in the companion Japan/China rubrics.
• Therapeutic Goods (Manufacturing Principles) Determination 2020 — its existence, its legal basis (s.36), and its operative effect (naming a specific PE009 edition, with Annexes 4/5/14 excluded) were confirmed via WebSearch summaries of tga.gov.au/resources/legislation/therapeutic-goods-manufacturing-principles-determination-2020 and independently corroborated by an industry compliance blog (SeerPharma, blog.seerpharma.com/navigating-the-pathway-of-tga-enforcement-of-the-pic/s-guide-to-gmp-for-medicines-and-apis) that quotes the Determination's own operative language ("The manufacture of therapeutic goods...must comply with applicable procedures and requirements in the PIC/S Guide to GMP") and the Annex 4/5/14 exclusion with reasons. Direct WebFetch of the Determination itself timed out this session and was not independently re-read as primary text — flagged as a residual verification gap, same caveat as above.
• PE009 edition/currency facts (PE009-15 in force 1 May 2021; PE009-16 in force 1 Feb 2022, Australian-Determination-adopted from 3 June 2024 with Annex 16 phased to 3 Sept 2024; PE009-17 in force 25 Aug 2023, Australian-Determination-adopted from 1 Sept 2025, Annexes 4/5/14 excluded) — confirmed via multiple independent WebSearch results including TGA's own page titles/snippets (tga.gov.au/resources/resource/guidance/pe009-pics-guide-gmp-medicinal-products, tga.gov.au/news/regulatory-decision-notices/update-manufacturing-principles-medicines-apis-sunscreens) and a regulatory-affairs firm's summary (arqon.com). Cross-checked across sources and consistent — treated as reliable, though (per the pattern above) not confirmed against a primary-document full read.
• GMP clearance pathways for overseas manufacturers (Australian manufacturing licence for domestic sites; MRA / Compliance Verification / TGA GMP Certification for overseas sites) — confirmed via WebSearch summary of TGA's own "1: Determining whether licensing or certification is required" user-guide page and the general "Overseas manufacturers" TGA page; direct WebFetch of both timed out this session and was not independently re-read as primary text.
• PIC/S PE009's Part I / Part II / 20-annex structure — the two-part (finished-dose-form GMP in Part I; API GMP, closely following ICH Q7, in Part II) plus numbered-annex structure is not independently re-verified against picscheme.org this session (a WebFetch of the PIC/S publications index returned only a version/date confirmation — PE009-17, 21 June 2023 — without a usable annex-by-annex list). The chapter/annex-numbering scheme used below (Part I Ch.1–9; Part II §1–20 approximating ICH Q7; Annexes 1–20 matching the EU GMP Vol.4 numbering already modeled in this project's gmp-gdp-rubric.md and eu-annex1-rubric.md) reflects cross-reference against this project's own existing, separately-sourced EU GMP rubric (PE009 and EU GMP Vol.4 share near-identical structure and annex numbering by design — PIC/S and the European Commission co-ordinate the two texts) rather than an independent fresh read of the PIC/S source this session. Flagged as [UNVERIFIED — flagged, not used for specific clause citations] wherever a row below cites only a chapter/section number without a specific sub-clause number confirmed by the primary source described next.
• Specific, sub-clause-level PE009 citations that ARE independently verified this session (Part I Clauses 1.4(xiv), 1.12, 1.13, 2.10, 2.11, 4.1, 5.23, 5.24; Annex 11 (title only); Annex 15 §1.1; Part II Clauses 2.16, 3.12, 6.10, 6.11, 6.14, and Part II Section 12) come from a primary TGA source, described next — these are the highest-confidence citations in this document and are marked accordingly in the tables below.

Enforcement / failure-pattern data (primary, TGA-published):

• "Common inspection deficiencies and trends" — Emmett Broderick, GMP Inspector, Manufacturing Quality Branch, Australian Government Department of Health, TGA — presented at GMP Forum 2023. Original URL https://www.tga.gov.au/sites/default/files/2023-04/presentation-gmp-common-inspection-deficiencies-and-trends.pdf (confirmed to exist via WebSearch result snippet) timed out on direct WebFetch this session; the identical PDF (same TGA branding, same tga.gov.au footer watermark on every slide, same presenter/title/deficiency data) was instead successfully read, page-by-page as page images, from a third-party mirror at zamann-pharma.com/wp-content/uploads/2026/02/presentation-gmp-common-inspection-deficiencies-and-trends.pdf. This is treated as a faithful copy of the genuine TGA-authored slide deck (internal TGA department attribution, tga.gov.au branding/footer on every page, and content fully consistent with TGA's own published deficiency-classification framework), but the file was not read from tga.gov.au's own server this session — flagged so a future session re-verifies directly against the original URL when tga.gov.au is reachable.
  • Covers overseas and domestic GMP inspections conducted January–December 2022, of API and finished-dosage-form manufacturers ("all categories excluding Biologicals"), assessed against PIC/S Guide to GMP PE009-15 (1 May 2021) — i.e. this deficiency data is one PE009 edition behind the current (PE009-17) text; the underlying clauses cited (documentation, training, validation, deviation investigation) have not materially changed numbering between PE009-15 and PE009-17 for the specific clauses quoted, but this is asserted from general PIC/S-revision-history knowledge, not independently diffed this session.
  • Named "Previous Trends" (i.e. the recurring top deficiency categories across prior years, not just 2022): Deviation & Complaint Investigations (Part I Clause 1.4(xiv)); Quality Risk Management (Part I Clauses 1.12 & 1.13); Computerised Systems (Annex 11); Qualification & Validation (Annex 15).
  • Named 2022's own most-cited deficiencies: Qualification & Validation; Investigation Management; Training; Documentation Systems (including data integrity) — the slide deck explicitly notes a "re-emergence of Training and Documentation into most common deficiencies" for 2022 specifically.
  • This is real, current-era, TGA-published, name-attributed inspection-deficiency data — the single strongest piece of sourcing in this document, and materially better-sourced than either the Japan or China GMP companion rubrics' failure-pattern sections (which relied on peer-reviewed/press coverage of a small number of named-company scandals rather than a regulator's own inspection-trend data). It is analogous in kind to the MHRA deficiency-trend data already used in gmp-gdp-rubric.md.
• Australian National Audit Office (ANAO), "Administering the Code of Good Manufacturing Practice for Prescription Medicines," Audit Report 2013–14 — a genuine, independent, primary Australian government source, but about the TGA's own administrative performance as a regulator (documentation of licensing/certification decisions, inspection-closeout timeliness, information-security practices), not about any named manufacturer's GMP non-compliance. Confirmed via WebSearch (title, publisher, report number, and a summary of findings — inspection SOPs not requiring inspectors to record how prior CAPA effectiveness was verified; inspection-report/closeout timeliness "well below" TGA's own targets). This report is now over a decade old (2013–14) and should not be read as describing TGA's current administrative practice — included here as background context on regulator-side process rigor, not as a current failure-pattern citation, and explicitly not used to support any requirement row below.
• No named, current-era (2023–2026) TGA enforcement action against a specific manufacturer — licence suspension, licence cancellation, GMP-clearance cancellation, or ARTG cancellation tied to a named company and a named GMP failure — was found or independently verified this session. A trade-press-style secondary source (australianmanufacturing.com.au) states TGA licensing updates included "two licences...suspended, and eight licences...revoked" in an unspecified recent period, but names no companies and gives no reasons, and TGA's own "Compliance actions and outcomes" and "Understanding good manufacturing practice (GMP) compliance signals" pages could not be fetched this session (both timed out on direct WebFetch). This is the single biggest enforcement-sourcing gap in this document — see Gaps section.

WebFetch failure pattern, stated explicitly: the majority of direct tga.gov.au WebFetch attempts this session timed out (60s) rather than returning an error page or 403 — a different failure mode than the "403 blocked" pattern noted in some companion rubrics' sourcing notes. This looks like a slow/rate-limited server rather than active bot-blocking, but was not diagnosed further. Every TGA-hosted-page claim in this document that is not attributed to the Broderick PDF mirror above rests on WebSearch result snippets/summaries of the TGA page, not an independent full-page read — flagged consistently throughout rather than only once, per this project's "never fabricate" rule.

Rubric legend

Each row: Requirement (plain language) → Citation → Evidence that demonstrates compliance → Common failure pattern

Failure-pattern cells are marked:

• [REPRESENTATIVE] — sourced from the TGA's own 2023 GMP Forum inspection-deficiency presentation (real, current-era, name-attributed TGA data, though read via a mirrored copy rather than tga.gov.au directly — see Sources) or a well-established GMP failure mode drawn from PE009's own structure/cross-reference to the already-modeled EU GMP rubric.
• [ANALOGOUS] — a real, confirmed pattern or finding that is structurally similar and instructive, but drawn from a different jurisdiction's enforcement (e.g. the EU GMP/MHRA data already in gmp-gdp-rubric.md) rather than a TGA-specific finding — included only where explicitly caveated inline.
• [UNVERIFIED — flagged, not used] — a claim that could not be independently verified this session (chiefly: specific sub-clause numbers for PE009 chapters/sections beyond the Broderick-PDF-confirmed set, and the "two suspended / eight revoked" licence-action statistic) and is therefore not used to support a specific requirement row's citation precision or failure-pattern content below.
• No [HISTORICAL] marker is used in this document — no verified "founding scandal" narrative for either PIC/S's own 1970 origin or the TGA's adoption of it was researched to the depth needed to cite one responsibly this session; PIC/S's founding is a multilateral mutual-recognition initiative rather than a single-incident-driven rule (unlike, e.g., the IBT scandal behind US GLP), so a HISTORICAL marker would likely be manufactured rather than found even with more research time.

PART A — TGA/Manufacturing Principles Determination Administrative Layer (TGA-specific, no PIC/S-text analogue)

PART B — PE009 Part I (Finished Pharmaceutical Products) — core chapters

(Part I's chapter structure mirrors EU GMP Volume 4 by design — PIC/S and the European Commission co-ordinate the two texts. Chapter numbers below follow that established, cross-referenced structure; only the sub-clause numbers explicitly confirmed via the Broderick TGA presentation this session are cited at clause-level precision — the rest are cited at chapter level and flagged accordingly.)

PART C — PE009 Part II (Active Pharmaceutical Ingredients — ICH Q7-aligned) — core sections

(Part II's ~20-section structure closely follows ICH Q7, "Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients" — this alignment is well-established, shared PIC/S/ICH/EU-GMP-Vol.4-Part-II text lineage, not independently re-verified section-by-section against picscheme.org this session. Only the specific clauses the Broderick TGA presentation confirmed are cited at clause-level precision.)

Cross-reference: PE009 (Australia/PIC/S) vs. EU GMP Vol. 4 vs. 21 CFR 210/211

Recommendation: extend this project's shared "Evidence Type" layer with Australia-specific tags — pe009_edition_effective_date_check, tga_gmp_clearance_pathway_evidence, annex_exclusion_gate — alongside the already-defined capa_log, change_control_log, csv_lifecycle_package, etc. Most substantive-requirement rows above (deviation investigation, training, validation, documentation) map cleanly onto evidence types already defined for the EU GMP rubric, given the shared text lineage; only the edition-currency-check and licence/clearance-pathway concepts are genuinely new, Australia-specific evidence types.

Gaps / follow-ups before this goes into production scoring

1. tga.gov.au direct WebFetch was largely unusable this session (consistent 60-second timeouts, not 403/blocked responses) — every specific claim attributed only to a WebSearch snippet/summary of a TGA page (rather than the Broderick PDF mirror) should be treated as secondary-sourced, not independently read as primary text, and re-verified directly against tga.gov.au in a future session when the site is reachable. This affects: the Manufacturing Principles Determination 2020's exact operative text, the Act's s.36/s.40 exact wording, the overseas-manufacturer GMP-clearance pathway page, the "GMP compliance signals" guidance page, and the "Compliance actions and outcomes" page. Recommend a dedicated follow-up session that retries these specific URLs, or sources the underlying PDFs (many TGA guidance documents, like the Broderick presentation, are downloadable PDFs that may fetch more reliably than the surrounding HTML page, or can be located via a mirror as was done here).
2. No named, current-era (2023–2026) TGA enforcement action against a specific manufacturer was found or verified this session — in contrast to the FDA 210/211 rubric's ~11 confirmed-real recent warning letters, or even the Japan GMP rubric's two named-company cases (Kobayashi Kako, Nichi-Iko). The only enforcement-adjacent data point found (a trade-press claim of "two licences suspended, eight revoked" in an unspecified period, from australianmanufacturing.com.au) names no companies and gives no reasons, and is explicitly marked [UNVERIFIED — flagged, not used] above. Recommend a dedicated follow-up targeting TGA's own "Market actions" page (tga.gov.au/safety/market-actions), the "Compliance actions and outcomes" page, and the ARTG's public cancelled-goods listing, ideally with a working WebSearch budget and successful tga.gov.au fetches, to find at least one named, current, GMP-specific compliance action before this rubric is used to calibrate severity weighting.
3. PE009 Part I Chapters 2, 3, 5, 6, 7, 8, 9 and Part II's non-confirmed sections (materials management, process equipment, packaging/labelling, storage/distribution, laboratory controls, change control, rejection/reuse, complaints/recalls, contract manufacturers, agents/brokers/traders, cell-culture/fermentation guidance) are cited at chapter/section level only, not sub-clause level, because this session's primary-source confirmation came entirely from one presentation (the Broderick PDF) that happened to quote specific clauses only from Part I Ch.1/2/4/5 and Part II §2/3/6/12. A dedicated follow-up session should independently fetch and read PE009-17's actual Part I and Part II text (via picscheme.org directly, or a reliable tga.gov.au PDF mirror) to bring the remaining chapters/sections up to the same sub-clause precision as rows 9–13 and 20–26 above, rather than relying indefinitely on the EU-GMP-cross-reference shortcut used for rows 8, 14, 15, 17, 18, 19, and 27.
4. The PIC/S PE009 Part I / Part II / 20-annex structure itself was not independently re-verified against picscheme.org this session — a WebFetch of the PIC/S publications index returned only a bare version/date confirmation (PE009-17, 21 June 2023) without a usable table of contents. The chapter/annex numbering used throughout this document rests on cross-reference against this project's own separately-sourced EU GMP rubric (gmp-gdp-rubric.md), which is a reasonable inference given PIC/S–EU text coordination is well-established, but is not the same as an independent fresh read of the PIC/S source — flag for the same follow-up session as item 3.
5. The "Australian Code of Good Manufacturing Practice for human blood and blood components..." (Version 1.0, April 2013) — the standard that applies in place of the excluded Annex 14 — was identified by name and version only (via the SeerPharma secondary source) and has not been separately researched to rubric depth. Recommend this as a candidate future rubric (structurally parallel to how this project treats GQP/GVP as future candidates in the Japan GMP rubric), not folded into this document.
6. The ANAO 2013–14 audit report is a decade-plus old and describes the regulator's own administrative performance, not manufacturer compliance — included in Sources purely as background context on TGA's historical process rigor, explicitly not used to support any requirement row's failure-pattern content. A follow-up session could check whether ANAO has published a more recent audit of TGA's GMP administration (none was found or searched for specifically this session).
7. PE009-15 vs. PE009-17 clause-numbering stability was asserted, not verified. The Broderick presentation's confirmed clause citations (rows 9–13, 20–26 above) were made against PE009-15 (1 May 2021) inspection data; this document presents them as citations against the current PE009-17 text on the general PIC/S-practice assumption that core Part I/Part II clause numbering is stable across editions differing mainly in annex content (PE009-16 added/updated Annex 16; PE009-17's only material change was a rewritten Annex 1) — but this was not independently diffed clause-by-clause between the three editions this session. Recommend a follow-up diff before treating rows 9–13/20–26's clause numbers as certainly identical in PE009-17 specifically.